Extensively StudiedMetabolic

Erythropoietin (EPO)

EPO

EPO | Red Blood Cell Stimulating Hormone

Half-life

4-12 hours (IV), ~25 hours (SubQ)

Chain length

165 amino acids

Reference frequency

1-3 times weekly depending on response

Research overview

DoseGear research brief

Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow cells promotes survival and maturation of red blood cell precursors, increasing oxygen-carrying capacity. Due to performance-enhancing effects, it is banned in competitive sports.

Mechanism of action

EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production. Under hypoxic stress, endogenous EPO production can increase up to 1000-fold, demonstrating the body's powerful oxygen-sensing regulatory system.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Endogenous kidney-derived glycoprotein; recombinant forms were developed as medicines.

What it is researched for

Anemia associated with kidney disease or chemotherapy through EPOR-supported erythroid-progenitor survival and maturation.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

No sourced lyophilized-vial injectable protocol is listed for this profile.

Safety context

Reported side effects

Injection site reactions
Headache
Hypertension
Joint pain
Flu-like symptoms

Contraindications & cautions

Uncontrolled hypertension
Pure red cell aplasia history
Hemoglobin >12 g/dL (increased cardiovascular risk)
Active malignancy (relative contraindication)

Scientific references

01
Erythropoietin regulation of red blood cell production
Scientific citationErythropoietin regulation of red blood cell production. PMC/NCBI (2020).
02
Erythropoietin Stimulating Agents
Scientific citationErythropoietin Stimulating Agents. StatPearls (NCBI Bookshelf) (2024).
03
Erythropoiesis-stimulating agents and other methods to enhance oxygen transport
Scientific citationErythropoiesis-stimulating agents and other methods to enhance oxygen transport. PMC (2008).
04
The mechanism of erythropoietin action
Scientific citationThe mechanism of erythropoietin action. PubMed (1992).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity